This advert was created by Lupin Healthcare and is intended for UK Healthcare Professionals only.
Click or scan the QR code to access the Prescribing and Adverse Event Reporting Information for Luforbec
Move asthma care beyond the blue inhaler with Luforbec 100/61,2
The 2024 joint BTS/NICE/SIGN asthma guideline marks a shift away from SABA-reliant asthma management, instead recommending ICS/formoterol-based pathways that both relieve symptoms and address underlying airway inflammation.1
The BTS/NICE/SIGN asthma guidelines recommend offering low-dose MART for patients with newly diagnosed asthma presenting highly symptomatic or with a severe exacerbation.1
A guideline-aligned, cost-saving choice1–3
• Indicated for MART in eligible adult patients with asthma2
• Combines beclometasone/formoterol in one extrafine formulation2
• Delivers therapeutic equivalence to the originator Fostair® (beclometasone/ formoterol) in a familiar pMDI device2,4,5
Click or scan the QR code to discover the Luforbec 100/6 MART action plan and patient user guide
Adult asthma: Luforbec 100/6 is indicated in the regular treatment of asthma in adults where use of a combination ICS/LABA is appropriate. Luforbec 100/6 can be used as Maintenance and Reliever Therapy (MART) in appropriate adult asthma patients.2
Acronyms: BTS, British Thoracic Society; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta2
-agonist; MART, Maintenance and Reliever Therapy; NHS,
National Health Service; NICE, National Institute for Health and Care Excellence; SABA, short- acting beta agonist; SIGN, Scottish Intercollegiate Guidelines Network.
• Offers a 52% saving vs. Fostair, with over £100 million in savings already delivered to the NHS to date (NHS list price)3,6
References: 1. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) [NG245]. Available at:
https://www.nice.
org.uk/guidance/ng245 (Accessed: July 2026). 2. Luforbec 100/6 pMDI Summary of Product Characteristics. Lupin Healthcare UK Limited. 3. NHS Prescribing Data and Savings to Date Analysis. Lupin Healthcare Data On File. 4. Therapeutic Equivalence. Lupin Healthcare Data On File. 5. Fostair 100/6 pMDI Summary of Product Characteristics. Chiesi Ltd. 6. British National Formulary. Beclometasone with formoterol Medicinal forms. Available at:
https://bnf.nice.org. uk/drugs/beclometasone-with-formoterol/medicinal-forms/ (Accessed: July 2026).
UK-LUF-2605-00009 | July 2026
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
